Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$220.83-1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Research Workspace
Put BIIB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 0% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBiogen's growth portfolio expansion and late-stage pipeline advancements are key to its value. Revenue grew 3% year over year, and the last quarter beat expectations significantly. The stock trades at 16× P/E versus a peer median of 22×, indicating it looks cheap on this basis. If BIIB cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 27% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. BIIB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 35 analysts currently covering BIIB (as of Sep 2026).
Based on 14 Wall Street analysts offering 12-month price targets for BIIB in the last 4 months.
Continue this research
Compare BIIB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BIIB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put BIIB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance late-stage pipeline with multiple registrational data readouts
Long-term data supports late-stage pipeline advancement.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $220.83
The last 12 months of price, then the range of analyst 12-month targets from today’s $220.83.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
New product launch expands growth portfolio for sustainable revenue.
New data suggests significant valuation concerns impacting growth potential.
Threatens: Complete and integrate Apellis Pharmaceuticals acquisition
Acquisition integration costs may hinder financial discipline.
Advances: Advance late-stage pipeline with multiple registrational data readouts
Higher guidance supports late-stage pipeline advancement.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Positive outlook on portfolio expansion and pipeline readouts.
Advances: Manage revenue decline
Positive EPS guidance supports revenue management objectives.
Advances: Manage revenue decline
Fresh Alzheimer's data supports revenue management efforts.